<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04468347</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-1451-A08</org_study_id>
    <nct_id>NCT04468347</nct_id>
  </id_info>
  <brief_title>Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease</brief_title>
  <official_title>18F-AV-1451 PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 study designed to evaluate imaging characteristics of flortaucipir in the
      preclinical, prodromal and dementia phases of Alzheimer's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Australian Imaging Biomarkers and Lifestyle Study (AIBL) is a multicenter
      multidisciplinary study of Alzheimer's disease and aging funded by the Commonwealth
      Scientific and Industrial Research Organisation (CSIRO) Flagship Initiative, involving
      research centers in both Victoria and Western Australia. The goal of the A08 protocol was to
      further investigate the positron emission tomography (PET) imaging results with flortaucipir
      in patients across the AD spectrum from individuals with subjective memory complaints (SMC)
      to those with dementia, based on recruitment into the parent AIBL study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flortaucipir PET Imaging (Quantitative)</measure>
    <time_frame>75 to 105 minutes postdose</time_frame>
    <description>Flortaucipir PET standardized uptake value ratio (SUVr). For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flortaucipir PET Imaging (Qualitative) and Relationship to Cognitive Status</measure>
    <time_frame>baseline scan</time_frame>
    <description>Scans were visually read independently by two expert readers at the sponsor who were blinded to any clinical information of the subjects that categorized scans into 3 categories: Advanced AD Scan Pattern (τAD++), Moderate AD Scan Pattern (τAD+), Not AD Scan Pattern (τAD-). For analysis, subjects with Advanced (τAD++) scans were analyzed vs. the combined Moderate and Not AD pattern groups (τAD+/τAD-)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Alzheimer's disease (AD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alzheimer's disease subjects receiving a flortaucipir PET scan at baseline and 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild cognitive impairment (MCI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild cognitive impairment subjects receiving a flortaucipir PET scan at baseline and 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjective memory complainers (SMC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjective memory complainers receiving a flortaucipir PET scan at baseline and 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitively normal (CN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cognitively normal subjects receiving a flortaucipir PET scan at baseline and 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flortaucipir F18</intervention_name>
    <description>IV injection, 240 megabecquerel (MBq) (6.5 mCi)</description>
    <arm_group_label>Alzheimer's disease (AD)</arm_group_label>
    <arm_group_label>Cognitively normal (CN)</arm_group_label>
    <arm_group_label>Mild cognitive impairment (MCI)</arm_group_label>
    <arm_group_label>Subjective memory complainers (SMC)</arm_group_label>
    <other_name>18F-AV-1451</other_name>
    <other_name>[F-18]T807</other_name>
    <other_name>LY3191748</other_name>
    <other_name>Tauvid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Brain PET scan</intervention_name>
    <description>positron emission tomography (PET) scan of the brain</description>
    <arm_group_label>Alzheimer's disease (AD)</arm_group_label>
    <arm_group_label>Cognitively normal (CN)</arm_group_label>
    <arm_group_label>Mild cognitive impairment (MCI)</arm_group_label>
    <arm_group_label>Subjective memory complainers (SMC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet all inclusion criteria for the AIBL study protocol, with amyloid PET conducted or
             planned and MRI available

          -  Subjects in the MCI and AD groups required to have a reliable caregiver capable of
             providing information about the subjects' symptoms

        Exclusion Criteria:

          -  lifetime history of schizophrenia, schizoaffective disorder, or bipolar disorder

          -  history of electroconvulsive therapy

          -  MRI contraindicated

          -  claustrophobic or, otherwise, unable to tolerate the imaging procedure

          -  current clinically significant cardiovascular disease or clinically significant
             abnormalities on screening electrocardiogram

          -  history of additional risk factors for Torsades de Pointes

          -  current clinically significant infectious disease, endocrine or metabolic disease, or
             pulmonary, renal, or hepatic impairment that the investigator believes would affect
             study participation

          -  history of cancer (other than skin or in situ prostate cancer) within the previous 5
             years

          -  current drug or alcohol abuse/dependence

          -  history of alcohol abuse/dependence with 2 years of the onset of the symptoms of
             dementia

          -  females of childbearing potential who were not surgically sterile, not refraining from
             sexual activity, or not using reliable methods of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Avid Radiopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <link>
    <url>http://aibl.csiro.au/</url>
    <description>Link to the Australian Imaging, Biomarker &amp; Lifestyle Flagship Study of Ageing (AIBL) website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>July 27, 2020</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

